Stocks · News reference

8-K filing — FENNEC PHARMACEUTICALS INC. (FENC)

Sep 17, 2026, 8:03 PMSEC EDGAR

Filed: 2026-09-17 AccNo: 0001104659-26-108565 Size: 220 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 17, 2026, 11:35 AMBenzinga Newsdesk
Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients
FENC
BenzingaSep 9, 2026, 11:18 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
FENC
BenzingaAug 12, 2026, 4:50 PMBenzinga Newsdesk
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
FENC